NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Adenocarcinoma
Endometrial Serous Adenocarcinoma
Uterine Carcinosarcoma
Endometrial Endometrioid Adenocarcinoma
Stage IVB Uterine Corpus Cancer AJCC v7
Uterine Corpus Carcinosarcoma
Recurrent Uterine Corpus Carcinoma
Stage IVA Uterine Corpus Cancer AJCC v7

Interventions: Drug: Sunitinib Malate

First Posted Date: 2007-05-24

Last Posted Date: 2020-02-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00478426

Locations: 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 26 locations

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Adenocarcinoma of the Extrahepatic Bile Duct
Recurrent Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer
Adenocarcinoma of the Gallbladder
Malignant Neoplasm
Unresectable Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer

Interventions: Biological: trastuzumab
Other: laboratory biomarker analysis

First Posted Date: 2007-05-24

Last Posted Date: 2019-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT00478140

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
The University of Texas (UT) MD Anderson Cancer Center, Houston, Texas, United States

Breast Mammogram and Tissue Study

Active, not recruiting

Conditions: Breast Neoplasms

First Posted Date: 2007-05-21

Last Posted Date: 2025-06-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 466

Registration Number: NCT00475761

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin
Drug: S-adenosyl methionine for Chronic Liver Disease

First Posted Date: 2007-05-21

Last Posted Date: 2013-07-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 24

Registration Number: NCT00475176

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer
Barrett Esophagus

Interventions: Drug: esomeprazole magnesium
Drug: acetylsalicylic acid
Other: placebo

First Posted Date: 2007-05-17

Last Posted Date: 2014-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 122

Registration Number: NCT00474903

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Secondary Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
de Novo Myelodysplastic Syndromes
Secondary Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2007-05-17

Last Posted Date: 2017-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00475150

Locations: 🇺🇸
Howard University Hospital, Washington, District of Columbia, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Recurrent Pancreatic Cancer
Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer

Interventions: Drug: dasatinib
Procedure: laboratory biomarker analysis
Procedure: physiologic testing

First Posted Date: 2007-05-17

Last Posted Date: 2015-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00474812

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Phase 2

Completed

Conditions: Distal Urethral Cancer
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Urethral Cancer Associated With Invasive Bladder Cancer

Interventions: Drug: pazopanib hydrochloride

First Posted Date: 2007-05-10

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00471536

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States

and more 6 locations

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

Not Applicable

Completed

Conditions: Hypogonadism

First Posted Date: 2007-05-08

Last Posted Date: 2011-04-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 40

Registration Number: NCT00470990

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Acral Lentiginous Malignant Melanoma
Recurrent Melanoma
Stage IIIA Melanoma
Stage IV Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2007-05-07

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00470470

Locations: 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States
🇺🇸
Mount Sinai Medical Center CCOP, Miami Beach, Florida, United States
🇺🇸
Good Samaritan Medical Center, West Palm Beach, Florida, United States

and more 5 locations

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Breast Mammogram and Tissue Study

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery